Safety and Performance of the Omnipod® Hybrid Closed-Loop System in Children Aged 6-12 Years with Type 1 Diabetes over Five Days Under Free-Living Conditions

The safety and performance of the Omnipod® hybrid closed-loop (HCL) personalized model predictive control algorithm was assessed in children with type 1 diabetes (T1D) using an investigational device over 5 days in a supervised hotel setting under free-living conditions. Eligible participants were a...

Full description

Saved in:
Bibliographic Details
Published in:Diabetes (New York, N.Y.) Vol. 67; no. Supplement_1
Main Authors: SHERR, JENNIFER, FORLENZA, GREGORY P., BUCKINGHAM, BRUCE, PEYSER, THOMAS A., LEE, JOON BOK, OCONNOR, JASON B., DUMAIS, BONNIE, HUYETT, LAUREN M., LAYNE, JENNIFER E., LY, TRANG T.
Format: Journal Article
Language:English
Published: 01-07-2018
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The safety and performance of the Omnipod® hybrid closed-loop (HCL) personalized model predictive control algorithm was assessed in children with type 1 diabetes (T1D) using an investigational device over 5 days in a supervised hotel setting under free-living conditions. Eligible participants were aged 6-11.9 y with A1C <10.0% using CSII or MDI. A 7-day open-loop (OL) phase of standard therapy (CSII/MDI) plus CGM use at home preceded the 96 h HCL phase. Meals during HCL were unrestricted, with boluses administered per usual routine. Moderate-intensity exercise was performed for ≥30 min/d. An adaptive approach was used to update participant parameters after the first 48 h of HCL. Fifteen participants (MDI n=3) were (mean ± SD): age 9.9 ± 1.0 y, diabetes duration 5.2 ± 2.0 y, A1C 8.0 ± 0.9% and TDD 0.84 ± 0.13 U/kg. Glycemic outcomes are reported in the table. The percentage of time 70-180 mg/dL was 14.3% higher during HCL compared to OL overall (HCL 69.2 ± 13.5 vs. OL 54.9 ± 12.8) and 20.4% higher overnight (HCL 73.8 ± 19.3 vs. OL 53.4 ± 18.8). A concomitant reduction in the percentage of time <70 mg/dL occurred during HCL vs. OL overall (HCL 2.2 ± 1.9 vs. OL 2.9 ± 2.4) and overnight (HCL 1.0 ± 1.9 vs. OL 2.6 ± 2.5). The Omnipod HCL system was safe and performed well over 5 days of use in children with T1D under free-living conditions with unrestricted meals and moderate-intensity exercise. Glycemic outcomes during hybrid closed-loop (HCL) and open-loop (OL) phasesGlycemic outcomesHCL OverallOL OverallHCL Night (23:00 - 06:59)OL Night (23:00 - 06:59)Mean glucose (mg/dL)156.3 ± 22.1177.5 ± 28.5154.8 ± 29.0177.6 ± 35.2Percent time <54 mg/dL (%)0.3 ± 0.40.6 ± 0.60.1 ± 0.40.8 ± 1.1Percent time <70 mg/dL (%)2.2 ± 1.92.9 ± 2.41.0 ± 1.92.6 ± 2.5Percent time 70-140 mg/dL (%)47.1 ± 12.334.5 ± 13.452.5 ± 18.432.7 ± 16.7Percent time 70-180 mg/dL (%)69.2 ± 13.554.9 ± 12.873.8 ± 19.353.4 ± 18.8Percent time >180 mg/dL (%)28.7 ± 14.142.2 ± 14.725.2 ± 19.744.0 ± 20.8Percent time ≥250 mg/dL (%)8.6 ± 8.817.5 ± 11.48.6 ± 11.716.5 ± 15.0
ISSN:0012-1797
1939-327X
DOI:10.2337/db18-1377-P